back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-04-11 13:06 Tx date 2024-04-01 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-55,000 vol |
835,000 | |
| Filed 2023-05-16 16:26 Tx date 2023-05-15 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
890,000 | |
| Filed 2023-05-10 11:53 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
650,000 | |
| Filed 2023-03-01 13:39 Tx date 2022-12-08 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$60,000
+600,000 vol $0.10 each |
1,367,618 | |
| Filed 2023-03-01 13:37 Tx date 2022-12-08 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$60,000
+600,000 vol $0.10 each |
||
| Filed 2022-12-09 14:21 Tx date 2022-12-08 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$60,000
+600,000 vol $0.10 each |
||
| Filed 2023-02-01 19:00 Tx date 2023-02-01 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,837
+17,500 vol $0.105 each |
875,632 | |
| Filed 2023-01-30 19:49 Tx date 2021-11-07 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-75,000 vol |
250,000 | |
| Filed 2023-01-30 19:46 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
550,000 | |
| Filed 2023-01-17 17:55 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$37,999
+422,222 vol $0.09 each |
858,132 | |
| Filed 2022-12-09 14:21 Tx date 2022-12-08 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$60,000
+600,000 vol $0.10 each |
1,240,000 | |
| Filed 2022-12-09 14:16 Tx date 2022-12-08 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-60,000
-600,000 vol $0.10 each |
640,000 | |
| Filed 2022-08-12 16:27 Tx date 2022-08-10 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+450,000 vol |
1,240,000 | |
| Filed 2022-07-26 13:35 Tx date 2021-08-13 |
$AVCR
Avricore Health Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-333,333 vol |
0 | |
| Filed 2021-08-17 12:15 Tx date 2021-08-12 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-31,500
-180,000 vol $0.175 each |
567,618 | |
| Filed 2021-08-16 17:19 Tx date 2021-08-12 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-35,000
-200,000 vol $0.175 each |
||
| Filed 2021-08-16 17:27 Tx date 2021-08-12 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$30,000
+200,000 vol $0.15 each |
747,618 | |
| Filed 2021-08-16 17:24 Tx date 2021-08-12 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-30,000
-200,000 vol $0.15 each |
333,333 | |
| Filed 2021-08-16 17:19 Tx date 2021-08-12 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-35,000
-200,000 vol $0.175 each |
547,618 | |
| Filed 2021-06-16 12:58 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+150,000 vol $0.40 each |
325,000 | |
| Filed 2021-06-03 11:43 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$12,899
+33,506 vol $0.385 each |
435,910 | |
| Filed 2021-05-27 12:56 Tx date 2021-05-17 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,633
+4,355 vol $0.375 each |
402,404 | |
| Filed 2021-04-19 23:40 Tx date 2021-04-19 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
790,000 | |
| Filed 2020-08-19 19:57 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$17,249
+95,833 vol $0.18 each |
398,049 | |
| Filed 2019-10-31 21:16 Tx date 2019-10-28 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+60,000 vol |
715,000 | |
| Filed 2019-10-29 15:22 Tx date 2019-10-29 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$14,249
+50,892 vol $0.28 each |
302,216 | |
| Filed 2019-09-17 16:28 Tx date 2019-09-13 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
16 - Acquisition or disposition under a prospectus exemption
|
$15,000
+37,500 vol $0.40 each |
37,500 | |
| Filed 2019-09-17 16:25 Tx date 2010-12-22 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-08-16 23:03 Tx date 2019-08-14 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$30,000
+200,000 vol $0.15 each |
533,333 | |
| Filed 2019-08-16 22:56 Tx date 2019-08-14 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+200,000 vol $0.05 each |
747,618 | |
| Filed 2019-06-13 10:41 Tx date 2019-04-01 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$3,300
+55,000 vol $0.06 each |
655,000 | |
| Filed 2019-03-19 Tx date 2019-03-15 |
$AVCR
Avricore Health Inc. (formerly Vanc Pharmaceuticals Inc.) |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$14,999
+214,285 vol $0.07 each |
547,618 | |
| Filed 2019-01-18 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$36,764
+77,398 vol $0.475 each |
251,324 | |
| Filed 2019-01-09 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,565,334 vol |
173,926 | |
| Filed 2019-01-09 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
175,000 | |
| Filed 2019-01-09 Tx date 2016-12-07 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
75,000 | |
| Filed 2018-05-16 Tx date 2017-12-06 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$52,500
+150,000 vol $0.35 each |
600,000 | |
| Filed 2018-05-16 Tx date 2017-12-06 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$157,500
+450,000 vol $0.35 each |
450,000 | |
| Filed 2017-06-28 Tx date 2017-06-26 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$66,666
+333,333 vol $0.20 each |
333,333 | |
| Filed 2017-06-28 Tx date 2016-01-21 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-06-28 Tx date 2017-06-26 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$49,999
+333,333 vol $0.15 each |
333,333 | |
| Filed 2017-06-28 Tx date 2016-01-21 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-05-12 Tx date 2017-01-27 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
38 - Redemption, retraction, cancellation, repurchase
|
-100,000 vol |
0 | |
| Filed 2016-11-25 Tx date 2016-11-21 |
$VANC
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-300,000 vol |
100,000 | |
| Filed 2016-06-02 Tx date 2016-06-01 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$72,000
+480,000 vol $0.15 each |
1,739,260 | |
| Filed 2016-06-02 Tx date 2016-05-31 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-72,000
-900,000 vol $0.08 each |
1,259,260 | |
| Filed 2016-04-06 Tx date 2016-04-05 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$125,000
+625,000 vol $0.20 each |
2,159,260 | |
| Filed 2016-04-06 Tx date 2016-03-31 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-25,000
-125,000 vol $0.20 each |
1,534,260 | |
| Filed 2016-04-06 Tx date 2016-03-31 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-99,999.90
-740,740 vol $0.135 each |
1,659,260 | |
| Filed 2016-01-25 Tx date 2016-01-21 |
$NPH
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$140,000
+400,000 vol $0.35 each |
400,000 | |
| Filed 2016-01-25 Tx date 2016-01-21 |
$NPH
Vanc Pharmaceuticals Inc. |
Hall, David M.
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|